As we enter into the closing months of 2023, it’s hard to deny that the year so far has been dominated by one of the most contentious and polarising topics in healthcare – drug pricing.
Little over a year since President Joe Biden signed the controversial Inflation Reduction Act (IRA) into law, it’s safe to say that the fight over the provisions aimed at lowering prescription drug costs is heating up. As of today, nine companies have filed lawsuits challenging the constitutionality of the new law, arguing that the IRA’s provisions may restrict investments in research development and curb innovation.
While the legislation may be a bitter pill for the industry to swallow, for patients the benefits are a welcome rebalance of power between pharma stakeholders and publicly appointed government representatives.
To help break down the core arguments for each side of the IRA debate, pharmaphorum editor-in-chief Jonah Comstock unpacks each legal challenge and explores the broader impact of the IRA for both industry and patients.
Elsewhere in this issue of Deep Dive, we take a look back at the storied history of the UK’s National Health Service to mark the organisation’s 75th anniversary, plus Lumanity’s Gagandeep Sawant and Lindsay Lare offer a simple framework to help guide companies along their journey of choosing the right omnichannel partner.
For all this and more, read on.
Eloise McLennan – editor, Deep Dive
For the best page-viewing experience, make sure you have your browser at full-screen size. Use the left/right arrow buttons to scroll through the pages or click on the menu icon bottom centre to navigate. You can also share the articles on social media by clicking the icon bottom left at the base of the main navigation or at the end of each article.